Literature DB >> 34791556

Evaluation of the Anti-Viral Activity of Human Recombinant Interferon Lambda-1 against SARS-CoV-2.

P G Madonov1, V A Svyatchenko2, S S Legostaev2, N A Kikhtenko1, A A Kotlyarova1, L A Oleinik3, G I Baikalov1.   

Abstract

The antiviral activity of recombinant human IFN-lambda type 1 (IFNλ-1) against culture strain of SARS-CoV-2 virus was determined by infecting a highly sensitive VeroE6 coronavirus cell culture after preincubation test (the cell monolayer was incubated with 4-fold dilutions of IFNλ-1 in a concentration range of 0.16-42,500 ng/ml in a culture medium for 12 h at 37°C) and without preincubation (simultaneous addition of different concentrations of IFNλ-1 and SARS-CoV-2 infection in a dose of 102 TCID50). The created recombinant human IFNλ-1 demonstrated obvious antiviral activity against SARS-CoV-2 virus in vitro. In the tests with and without preincubation, IFNλ-1 exhibited significant activity, although somewhat lower in variant with simultaneous addition of IFNλ-1 and virus to the cell culture. It should be noted that the antiviral effect of IFNλ-1 was observed in a wide range of concentrations.
© 2021. Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  SARS-CoV-2; recombinant human interferon λ-1; specific antiviral activity

Mesh:

Substances:

Year:  2021        PMID: 34791556      PMCID: PMC8598276          DOI: 10.1007/s10517-021-05330-0

Source DB:  PubMed          Journal:  Bull Exp Biol Med        ISSN: 0007-4888            Impact factor:   0.804


  5 in total

1.  Innate IFN-lambda responses to dsRNA in the human infant airway epithelium and clinical regulatory factors during viral respiratory infections in early life.

Authors:  Kyle Salka; Maria Arroyo; Elizabeth Chorvinsky; Karima Abutaleb; Geovanny F Perez; Seth Wolf; Xilei Xuchen; Jered Weinstock; Maria J Gutierrez; Marcos Pérez-Losada; Dinesh K Pillai; Gustavo Nino
Journal:  Clin Exp Allergy       Date:  2020-07-26       Impact factor: 5.018

2.  Pseudomonas aeruginosa Can Degrade Interferon λ, Thereby Repressing the Antiviral Response of Bronchial Epithelial Cells.

Authors:  Adeline Peignier; Dane Parker
Journal:  J Interferon Cytokine Res       Date:  2020-07-14       Impact factor: 3.657

3.  Weak Induction of Interferon Expression by Severe Acute Respiratory Syndrome Coronavirus 2 Supports Clinical Trials of Interferon-λ to Treat Early Coronavirus Disease 2019.

Authors:  Thomas R O'Brien; David L Thomas; Sarah S Jackson; Ludmila Prokunina-Olsson; Raymond P Donnelly; Rune Hartmann
Journal:  Clin Infect Dis       Date:  2020-09-12       Impact factor: 9.079

4.  Antiviral Activity of Type I, II, and III Interferons Counterbalances ACE2 Inducibility and Restricts SARS-CoV-2.

Authors:  Idoia Busnadiego; Sonja Fernbach; Marie O Pohl; Umut Karakus; Michael Huber; Alexandra Trkola; Silke Stertz; Benjamin G Hale
Journal:  mBio       Date:  2020-09-10       Impact factor: 7.867

5.  A mouse-adapted model of SARS-CoV-2 to test COVID-19 countermeasures.

Authors:  Kenneth H Dinnon; Sarah R Leist; Alexandra Schäfer; Caitlin E Edwards; David R Martinez; Stephanie A Montgomery; Ande West; Boyd L Yount; Yixuan J Hou; Lily E Adams; Kendra L Gully; Ariane J Brown; Emily Huang; Matthew D Bryant; Ingrid C Choong; Jeffrey S Glenn; Lisa E Gralinski; Timothy P Sheahan; Ralph S Baric
Journal:  Nature       Date:  2020-08-27       Impact factor: 49.962

  5 in total
  2 in total

1.  Impact of COVID-19 on the liver and on the care of patients with chronic liver disease, hepatobiliary cancer, and liver transplantation: An updated EASL position paper.

Authors:  Thomas Marjot; Christiane S Eberhardt; Tobias Boettler; Luca S Belli; Marina Berenguer; Maria Buti; Rajiv Jalan; Mario U Mondelli; Richard Moreau; Daniel Shouval; Thomas Berg; Markus Cornberg
Journal:  J Hepatol       Date:  2022-07-20       Impact factor: 30.083

2.  Pharmacokinetic Parameters of Oral Pegylated IFN-λ1.

Authors:  E Yu Sherstoboev; L A Oleinik; V V Zhdanov; N A Kikhtenko; P G Madonov
Journal:  Bull Exp Biol Med       Date:  2022-06-23       Impact factor: 0.737

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.